VivoSeq
Other

Arthroplasty, Replacement, Hip

0

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

Arthroplasty, Replacement, Hip is an early-stage landscape with 0 programs across 2 companies. The most active players are Milestone Pharmaceuticals Inc., Stryker Orthopaedics.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Milestone Pharmaceuticals Inc.

1 program

Phase 2S

Stryker Orthopaedics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Not yet recruiting1 · 33%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement. The ABOGRAFT Trial
Recruiting·UUniversity Hospital, Linkoeping·Phase 2·NCT05169229·1,100 enrolled
Multimodal Analgesic Regimen for Total Hip Arthroplasty: An Initiative to Minimize Postoperative Opioid Use
Not yet recruiting·HHenry Ford Health System·Preclinical·NCT07672808·100 enrolled
A Prospective, Post-market, Multi-center Study of the Trident II Tritanium Acetabular Shell
Active, not recruiting·—·Preclinical·NCT02999009·383 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)